We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis.
- Authors
Nakano, Kenji; Nishizawa, Masatoshi; Fukuda, Naoki; Urasaki, Tetsuya; Wang, Xiaofei; Mitani, Hiroki; Takahashi, Shunji
- Abstract
Immune checkpoint inhibitors (ICIs) are now widely used to many malignant diseases, but some patients suffer from immune-related adverse events during or after ICI treatments. The monoclonal antibody infliximab is usually chosen as a salvage treatment to combat corticosteroid-resistant adverse events, but infliximab is not recommended as a response to hepatitis because of the potential risk of liver failure. An alternative treatment option has not been established. We treated a head and neck cancer patient (a 50-year-old Japanese male) who suffered from corticosteroid-resistant hepatitis during treatment with nivolumab, an anti-PD-1 ICI, and that was recovered by mycophenolate mofetil salvage therapy.
- Subjects
MYCOPHENOLIC acid; IMMUNE checkpoint inhibitors; HEPATITIS; CHRONIC active hepatitis; LIVER failure; SALVAGE therapy; HEAD &; neck cancer
- Publication
Oxford Medical Case Reports, 2020, Vol 20, Issue 4/5, p1
- ISSN
2053-8855
- Publication type
Article
- DOI
10.1093/omcr/omaa027